Comprehensive Guide to Mepolizumab: Uses, Dosage, Side Effects, and More

What is Mepolizumab?

Overview of Mepolizumab

Generic Name: Mepolizumab

Brand Name: Nucala

Drug Group: Monoclonal antibody (biologic, anti-IL-5)

Commonly Used For

This medication is used to:

• Treat severe eosinophilic asthma.
• Manage eosinophilic granulomatosis with polyangiitis (EGPA).
• Control chronic rhinosinusitis with nasal polyps.

Key Characteristics

Form: Subcutaneous injection (100 mg/vial) (detailed in Dosage section).

Mechanism: Binds IL-5, inhibiting eosinophil maturation, activation, and survival.

Approval: FDA-approved (2015 for Nucala) and EMA-approved for asthma and EGPA.

Indications and Uses of Mepolizumab

Mepolizumab is indicated for eosinophilic inflammatory conditions, leveraging its targeted IL-5 inhibition:

Severe Eosinophilic Asthma: Treats patients (6+ years) with uncontrolled asthma despite high-dose inhaled corticosteroids, reducing exacerbations and improving lung function, supported by MENSA and MUSCA trials.

Eosinophilic Granulomatosis with Polyangiitis (EGPA): Manages EGPA in adults with relapsing or refractory disease, decreasing oral corticosteroid use, per MIRRA trial data.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Approved for adults to reduce nasal polyp size and improve symptoms, enhancing quality of life, with evidence from SYNAPSE trial.

Hypereosinophilic Syndrome (HES): Used off-label to control HES in patients unresponsive to standard therapies, reducing eosinophil counts, supported by hematology studies.

Eosinophilic Esophagitis (EoE): Investigated off-label to alleviate esophageal inflammation and dysphagia in EoE, with promising gastroenterology research.

Allergic Bronchopulmonary Aspergillosis (ABPA): Explored off-label in ABPA with severe asthma, improving lung function, with data from pulmonary medicine cohorts.

Chronic Obstructive Pulmonary Disease (COPD) with Eosinophilia: Studied off-label to reduce exacerbations in COPD patients with elevated eosinophils, with emerging respiratory research.

Atopic Dermatitis with Eosinophilia: Managed off-label to control severe atopic dermatitis with eosinophilic involvement, supported by dermatology trials.

Churg-Strauss Syndrome Variants: Used off-label to manage variants of EGPA with systemic vasculitis, improving remission rates, noted in rheumatology studies.

Eosinophilic Pneumonia: Investigated off-label for acute or chronic eosinophilic pneumonia, reducing lung inflammation, with preliminary pulmonology evidence.

Dosage of Mepolizumab

Dosage for Adults

• Severe Eosinophilic Asthma: 100 mg subcutaneous (SC) every 4 weeks.
• Eosinophilic Granulomatosis with Polyangiitis (EGPA): 300 mg SC (three 100 mg injections) every 4 weeks.
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): 100 mg SC every 4 weeks.

Dosage for Children

Severe Eosinophilic Asthma (6–11 years):

• 40 mg SC every 4 weeks if <40 kg; 100 mg SC every 4 weeks if ≥40 kg, under pediatric pulmonologist supervision.
• 12–17 years: 100 mg SC every 4 weeks.

Not recommended under 6 years.

Dosage for Pregnant Women

Pregnancy Category B: Limited data; use only if benefits outweigh risks (e.g., severe asthma). Consult an obstetrician, with fetal monitoring.

Dosage Adjustments

Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).

Hepatic Impairment: No adjustment needed; monitor in severe cases (Child-Pugh C).

Elderly: Start with 100 mg every 4 weeks; increase to 300 mg if tolerated for EGPA.

Concomitant Immunosuppressants: Adjust if combined with high-dose corticosteroids, monitoring immune response.

Additional Considerations

• Administer this active ingredient via SC injection in the upper arm, thigh, or abdomen by a healthcare provider or trained patient.
• Rotate injection sites to prevent irritation.

How to Use Mepolizumab

Administration:

• Reconstitute with sterile water, allow to stand for 5–10 minutes, and inject SC over 5–10 seconds; avoid intravascular injection.
• Administer in a clinical setting or by trained patients with proper technique.

Timing: Use every 4 weeks, scheduling appointments or self-injections consistently.

Monitoring: Watch for injection site reactions, fatigue, or signs of hypersensitivity (e.g., swelling).

Additional Tips:

• Store at 2–8°C (36–46°F); do not freeze or shake vigorously.
• Keep out of reach of children due to biologic risk.
• Report severe pain, rash, or signs of infection immediately.

Contraindications for Mepolizumab

This drug is contraindicated in:

Hypersensitivity: Patients with a known allergy to Mepolizumab or its components.

Severe Active Infections: Avoid during untreated systemic infections due to immunosuppression risk.

Pregnancy: Contraindicated unless life-saving, with limited safety data.

Warnings & Precautions

General Warnings

Hypersensitivity Reactions: Risk of anaphylaxis; monitor for 30 minutes post-injection.

Parasitic Infections: Increased risk if exposed; screen and treat before use.

Immunosuppression: Reduced immune response; avoid live vaccines.

Eosinophilic Myocarditis: Rare risk; assess cardiac symptoms.

Injection Site Reactions: Pain, swelling, or erythema; rotate sites.

Additional Warnings

Herpes Zoster Reactivation: Increased risk; monitor for shingles.

Neurological Effects: Rare peripheral neuropathy; report numbness.

Malignancy Risk: Theoretical risk with long-term use; monitor closely.

Bone Density Loss: Potential risk with prolonged therapy; assess osteoporosis.

Hypersensitivity Reactions: Delayed reactions possible; educate patients.

Use in Specific Populations

Pregnancy: Category B; use only if essential with fetal monitoring.

Breastfeeding: Excreted in breast milk; monitor infant for effects.

Elderly: Higher risk of infections; start with standard dosing.

Children: Limited to 6+ years; supervise closely.

Renal/Hepatic Impairment: No adjustment; monitor in severe cases.

Additional Precautions

• Inform your doctor about infections, allergies, or prior vaccinations before starting this medication.
• Avoid abrupt cessation; taper if combined with corticosteroids.

Overdose and Management

Overdose Symptoms

• Injection site reactions, fatigue, or headache.
• Severe cases: Hypersensitivity, eosinophil depletion, or immune suppression.
• Fever, rash, or muscle pain as early signs.
• Systemic inflammation with extremely high doses.

Immediate Actions

Contact the Medical Team: Seek immediate medical help.

Supportive Care: Monitor vital signs, manage allergic reactions with antihistamines or epinephrine if needed, and provide IV fluids.

Specific Treatment: No antidote; observe for 24–48 hours.

Monitor: Check eosinophil levels, liver function, and cardiac status.

Additional Notes

• Overdose risk is low; store securely.
• Report persistent symptoms (e.g., severe rash, weakness) promptly.

Side Effects of Mepolizumab

Common Side Effects

• Injection Site Reactions (10–15%, manageable with ice)
• Headache (8–12%, relieved with rest)
• Fatigue (5–10%, decreases with tolerance)
• Nasopharyngitis (4–9%, treat with supportive care)
• Back Pain (3–7%, improved with stretching)

These effects may subside with continued use.

Serious Side Effects

Additional Notes

• Regular monitoring for eosinophil levels, infection risk, and cardiac health is advised.
• Report any unusual symptoms (e.g., difficulty breathing, severe fatigue) immediately to a healthcare provider.

Drug Interactions with Mepolizumab

This active ingredient may interact with:

• Live Vaccines: Reduces efficacy; avoid during therapy.
• Immunosuppressants: Enhances immune suppression (e.g., cyclosporine); monitor.
• Corticosteroids: May alter eosinophil response; adjust dose.
• Antihistamines: Potential overlap in allergy management; use cautiously.
• Antibiotics: Alters infection prophylaxis; consult provider.

Action: Provide your healthcare provider with a complete list of medications.

Patient Education or Lifestyle

Pharmacokinetics of Mepolizumab

Absorption: Well-absorbed SC (peak at 4–8 days); bioavailability ~80%.

Distribution: Volume of distribution ~3.6 L; 65–75% protein-bound.

Metabolism: Degraded via proteolytic pathways to small peptides.

Excretion: Minimal renal clearance (<4%); half-life 16–22 days.

Half-Life: 16–22 days, with sustained eosinophil reduction.

Pharmacodynamics of Mepolizumab

This drug exerts its effects by:

Binding IL-5 with high affinity, neutralizing its activity and reducing eosinophil production.

Decreasing airway inflammation and remodeling in asthma.

Improving systemic vasculitis symptoms in EGPA.

Exhibiting dose-dependent risks of infection and hypersensitivity.

Storage

Temperature: Store at 2–8°C (36–46°F); do not freeze or shake vigorously.

Protection: Keep in original carton to protect from light.

Safety: Store out of reach of children due to biologic risk.

Disposal: Dispose of used syringes per biohazard regulations or consult a pharmacist.

Frequently Asked Questions (FAQs)

Q: What does Mepolizumab treat?

A: This medication treats severe eosinophilic asthma and EGPA.

Q: Can this active ingredient cause headaches?

A: Yes, headaches may occur; rest or hydration helps.

Q: Is Mepolizumab safe for children?

A: Yes, for 6+ years with a doctor’s guidance.

Q: How is this drug taken?

A: Via SC injection every 4 weeks, as directed.

Q: How long is Mepolizumab treatment?

A: Long-term for chronic conditions with monitoring.

Q: Can I use Mepolizumab if pregnant?

A: Yes, with caution; consult a doctor.

Regulatory Information

This medication is approved by:

U.S. Food and Drug Administration (FDA): Approved in 2015 (Nucala) for severe eosinophilic asthma, later expanded to EGPA and CRSwNP.

European Medicines Agency (EMA): Approved for asthma, EGPA, and CRSwNP.

Other Agencies: Approved globally for eosinophilic disorders; consult local guidelines.

References

1. U.S. Food and Drug Administration (FDA). (2023). Nucala (Mepolizumab) Prescribing Information.
   • Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
2. European Medicines Agency (EMA). (2023). Mepolizumab Summary of Product Characteristics.
   • EMA’s comprehensive information on the medication’s indications and precautions in Europe.
3. National Institutes of Health (NIH). (2023). Mepolizumab: MedlinePlus Drug Information.
   • NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
4. World Health Organization (WHO). (2023). WHO Guidelines on Asthma Management: Mepolizumab.
   • WHO’s recommendations for Mepolizumab in asthma care.
5. New England Journal of Medicine. (2022). Mepolizumab in EGPA.
   • Peer-reviewed article on Mepolizumab efficacy (note: access may require a subscription).

Disclaimer: This article provides general information about Mepolizumab for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider, such as an allergist, pulmonologist, or primary care physician, before using this drug or making any medical decisions. Improper use of this active ingredient can lead to serious health risks, including hypersensitivity reactions or impaired immune response.